vs

Side-by-side financial comparison of Perfect Moment Ltd. (PMNT) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.7M, roughly 1.1× Perfect Moment Ltd.). Perfect Moment Ltd. runs the higher net margin — 0.8% vs -1398.3%, a 1399.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 0.8%). Perfect Moment Ltd. produced more free cash flow last quarter ($2.2M vs $-156.9M).

Perfect Moment Ltd is a premium lifestyle and outdoor apparel brand specializing in high-performance, fashionable winter sports gear including ski wear, activewear, and supporting accessories. It serves luxury outdoor and winter sports consumer groups, with sales networks covering core markets in North America, Europe, and the Asia Pacific region.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

PMNT vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.7M
PMNT
Growing faster (revenue YoY)
RNA
RNA
+433.3% gap
RNA
434.0%
0.8%
PMNT
Higher net margin
PMNT
PMNT
1399.1% more per $
PMNT
0.8%
-1398.3%
RNA
More free cash flow
PMNT
PMNT
$159.1M more FCF
PMNT
$2.2M
$-156.9M
RNA

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
PMNT
PMNT
RNA
RNA
Revenue
$11.7M
$12.5M
Net Profit
$93.0K
$-174.4M
Gross Margin
64.4%
Operating Margin
5.0%
-1513.5%
Net Margin
0.8%
-1398.3%
Revenue YoY
0.8%
434.0%
Net Profit YoY
103.7%
-117.0%
EPS (diluted)
$0.00
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PMNT
PMNT
RNA
RNA
Q4 25
$11.7M
Q3 25
$4.8M
$12.5M
Q2 25
$1.5M
$3.8M
Q1 25
$5.0M
$1.6M
Q4 24
$11.7M
$3.0M
Q3 24
$3.8M
$2.3M
Q2 24
$2.0M
Q1 24
$3.5M
Net Profit
PMNT
PMNT
RNA
RNA
Q4 25
$93.0K
Q3 25
$-1.8M
$-174.4M
Q2 25
$-3.8M
$-157.3M
Q1 25
$-7.3M
$-115.8M
Q4 24
$-2.5M
$-102.3M
Q3 24
$-2.7M
$-80.4M
Q2 24
$-70.8M
Q1 24
$-68.9M
Gross Margin
PMNT
PMNT
RNA
RNA
Q4 25
64.4%
Q3 25
60.1%
Q2 25
60.4%
Q1 25
32.0%
Q4 24
54.8%
Q3 24
54.0%
Q2 24
Q1 24
Operating Margin
PMNT
PMNT
RNA
RNA
Q4 25
5.0%
Q3 25
-23.9%
-1513.5%
Q2 25
-207.5%
-4448.7%
Q1 25
-130.1%
-8360.9%
Q4 24
-11.1%
-4069.6%
Q3 24
-66.7%
-4200.9%
Q2 24
-4040.4%
Q1 24
-2178.6%
Net Margin
PMNT
PMNT
RNA
RNA
Q4 25
0.8%
Q3 25
-38.6%
-1398.3%
Q2 25
-259.4%
-4089.3%
Q1 25
-145.5%
-7360.0%
Q4 24
-21.3%
-3439.5%
Q3 24
-71.6%
-3441.7%
Q2 24
-3461.8%
Q1 24
-1943.4%
EPS (diluted)
PMNT
PMNT
RNA
RNA
Q4 25
$0.00
Q3 25
$-0.06
$-1.27
Q2 25
$-0.21
$-1.21
Q1 25
$-0.45
$-0.90
Q4 24
$-0.15
$-0.80
Q3 24
$-0.17
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PMNT
PMNT
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$1.6M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.1M
$1.9B
Total Assets
$13.8M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PMNT
PMNT
RNA
RNA
Q4 25
$1.6M
Q3 25
$393.0K
$350.2M
Q2 25
$3.0M
$243.9M
Q1 25
$6.2M
$254.2M
Q4 24
$2.8M
$219.9M
Q3 24
$725.0K
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Total Debt
PMNT
PMNT
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.9M
Q3 24
$1.8M
Q2 24
Q1 24
Stockholders' Equity
PMNT
PMNT
RNA
RNA
Q4 25
$1.1M
Q3 25
$981.0K
$1.9B
Q2 25
$987.0K
$1.2B
Q1 25
$1.9M
$1.3B
Q4 24
$907.0K
$1.4B
Q3 24
$2.7M
$1.5B
Q2 24
$1.2B
Q1 24
$830.9M
Total Assets
PMNT
PMNT
RNA
RNA
Q4 25
$13.8M
Q3 25
$15.0M
$2.1B
Q2 25
$8.3M
$1.4B
Q1 25
$13.3M
$1.5B
Q4 24
$13.2M
$1.6B
Q3 24
$13.3M
$1.6B
Q2 24
$1.3B
Q1 24
$951.5M
Debt / Equity
PMNT
PMNT
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
2.11×
Q3 24
0.67×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PMNT
PMNT
RNA
RNA
Operating Cash FlowLast quarter
$2.3M
$-156.2M
Free Cash FlowOCF − Capex
$2.2M
$-156.9M
FCF MarginFCF / Revenue
19.1%
-1257.6%
Capex IntensityCapex / Revenue
0.3%
5.7%
Cash ConversionOCF / Net Profit
24.26×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PMNT
PMNT
RNA
RNA
Q4 25
$2.3M
Q3 25
$-7.2M
$-156.2M
Q2 25
$-3.9M
$-199.7M
Q1 25
$-1.1M
$-124.8M
Q4 24
$-1.0M
$-99.9M
Q3 24
$-3.9M
$-65.6M
Q2 24
$-65.0M
Q1 24
$-70.4M
Free Cash Flow
PMNT
PMNT
RNA
RNA
Q4 25
$2.2M
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-1.1M
$-128.6M
Q4 24
$-1.2M
$-103.8M
Q3 24
$-3.9M
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
PMNT
PMNT
RNA
RNA
Q4 25
19.1%
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-21.8%
-8174.3%
Q4 24
-10.6%
-3491.0%
Q3 24
-101.5%
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
PMNT
PMNT
RNA
RNA
Q4 25
0.3%
Q3 25
5.7%
Q2 25
86.9%
Q1 25
0.3%
238.6%
Q4 24
1.6%
131.7%
Q3 24
1.0%
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
PMNT
PMNT
RNA
RNA
Q4 25
24.26×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons